Cargando…
Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial
INTRODUCTION: We have recently described an increased lymphocytic infiltration rate in breast carcinoma tissue is a significant response predictor for anthracycline/taxane-based neoadjuvant chemotherapy (NACT). The aim of this study was to prospectively validate the tumor-associated lymphocyte infil...
Autores principales: | Issa-Nummer, Yasmin, Darb-Esfahani, Silvia, Loibl, Sibylle, Kunz, Georg, Nekljudova, Valentina, Schrader, Iris, Sinn, Bruno Valentin, Ulmer, Hans-Ullrich, Kronenwett, Ralf, Just, Marianne, Kühn, Thorsten, Diebold, Kurt, Untch, Michael, Holms, Frank, Blohmer, Jens-Uwe, Habeck, Jörg-Olaf, Dietel, Manfred, Overkamp, Friedrich, Krabisch, Petra, von Minckwitz, Gunter, Denkert, Carsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846472/ https://www.ncbi.nlm.nih.gov/pubmed/24312450 http://dx.doi.org/10.1371/journal.pone.0079775 |
Ejemplares similares
-
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto
por: Laakmann, Elena, et al.
Publicado: (2019) -
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial
por: Witzel, I, et al.
Publicado: (2012) -
Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019) -
The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy
por: Wimberger, Pauline, et al.
Publicado: (2023) -
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)